PAW-hydrogel to help chronic wounds like diabetic foot and leg ulcers heal faster
Official title: Efficacy and Safety of a Carbopol® 940 Hydrogel Functionalized With Plasma-Activated Water (PAW) in the Treatment of Chronic Wounds: A Randomized Controlled Trial
Run by National Institute of Nuclear Research - Mexico · NCT07541196 · Data updated 2026-11-12
This trial will test whether a plasma-activated water–infused Carbopol® 940 hydrogel helps adults with long-standing wounds (diabetic foot, pressure, venous, arterial, or dehiscent ulcers) heal faster and have less bacteria compared with standard advanced wound care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | National Institute of Nuclear Research - Mexico Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ocoyoacac, State of Mexico) |
| Status | Recruiting |
| Started | April 20, 2026 |
| Main results expected | April 30, 2027 |
| Study ends | July 30, 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07541196 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with chronic wounds (>3 months) and wound surface area between 2 and 20 cm²—including Wagner grade 1–2 diabetic foot ulcers, pressure injuries grade I–III, dehiscent surgical wounds, and venous or arterial ulcers—with diabetic patients having HbA1c < 9% are ideal candidates.
✕Probably not a fit
Patients with clinical or radiologic osteomyelitis, severe arterial insufficiency (ABI < 0.5), active malignancy or immunosuppression, pregnancy, or wounds outside the size/duration criteria are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized, controlled, parallel-group trial comparing a PAW-functionalized Carbopol® 940 hydrogel applied 2–3 times weekly with standard advanced wound care in adults with chronic wounds that have failed to heal for more than three months. Participants are randomized 1:1 and treated at the Wound Clinic of Centro Médico ISSEMYM in collaboration with the Instituto Nacional de Investigaciones Nucleares, with PAW-hydrogel manufactured and quality-tested at ININ. Primary outcomes include wound area reduction by planimetry and changes in bacterial load, and safety will be monitored through local adverse events and pain reporting. The hydrogel is applied as a uniform 3–5 mm layer after cleansing, with regular follow-up visits for wound measurement and culture sampling.
Why it matters
Potential benefit: If successful, the PAW-hydrogel could speed wound closure, reduce bacterial burden, and lower the risk of infection or more invasive treatments for people with chronic wounds.
How similar studies have gone: Laboratory studies and small clinical reports of plasma-activated water and cold-plasma treatments show promising antimicrobial and healing effects, but PAW-functionalized hydrogels have limited clinical data and are relatively novel in practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age. * Diagnosis of chronic wound (diabetic foot ulcer Wagner grade 1-2, pressure injury grade I-III, dehiscent surgical wound, venous or arterial ulcer) with duration \> 3 months. * Wound surface area between 2 cm² and 20 cm². * For diabetic patients: HbA1c \< 9% (stable metabolic control). * Able and willing to provide written informed consent. Exclusion Criteria: * Clinical or radiological evidence of osteomyelitis (Wagner grade \> 3). * Severe arterial insufficiency (ankle-brachial index \< 0.5). * Use of systemic corticosteroids or immunosuppressants. * Pregnancy or lactation. * Known autoimmune skin disease (e.g., pemphigus, epidermolysis bullosa). * Active malignancy or undergoing chemotherapy/radiotherapy. * Participation in another interventional clinical trial within 30 days prior to screening.
Where it's running
-
Plasma Physics Laboratory, National Institute of Nuclear Research
Ocoyoacac, State of Mexico, Mexico Recruiting
Study contacts
- Study coordinator: Régulo López-Callejas, PhD
- Email: regulo.lopez@inin.gob.mx
- Phone: +52 5553297200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Amnion grafts for hard-to-heal diabetic foot and venous leg ulcers
This study will test whether two types of amnion grafts, added to standard wound care, help hard-to-heal diabetic foot and venous leg ulcers heal better.
-
Combination Bionerv E+ vs Vitamin B Complex in Type 2 Diabetes with DSPN and Foot Ulcers
In people with type 2 diabetes and diabetic polyneuropathy, this study tests whether adding alpha-lipoic acid and vitamin E to a vitamin B mix helps nerve symptoms and wound healing better than the vitamin B mix alone.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Wound gel for diabetic foot ulcers compared with standard care
This study tests whether the investigational VES-0-D wound gel helps heal mild to moderate diabetic foot ulcers better than standard treatment.
-
High-Purity Collagen Skin Substitute vs Fish Skin Matrix for Diabetic Foot Ulcers
This study tests whether a high-purity type-I collagen skin substitute works better than an acellular fish-skin matrix, when added to standard wound care, for healing diabetic foot ulcers.
-
L-Carnitine as an add-on for healing diabetic foot ulcers
This study tests whether taking L-Carnitine helps wound healing in adults with diabetic foot ulcers, alongside standard diabetes and wound care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.